Eva-Lotta Allan
Director/Board Member at ALMIRALL, S.A.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
John McCafferty | M | 66 |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 4 years |
Paul Rennert | M | - |
Aleta Biotherapeutics, Inc.
Aleta Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aleta Biotherapeutics, Inc. engages in the immuno-oncology service that focuses on transforming cellular therapeutics. It allows broad spectrum of cancer indication to be targeted including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb and is headquartered in Natick, MA. | 8 years |
Andrew Hotchkiss | M | - |
Draupnir Bio ApS
Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark. | 3 years |
Aneesh Karatt-Vellatt | M | 37 |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 4 years |
John Bell | M | 71 | 9 years | |
Simon Glerup Pedersen | M | - |
Draupnir Bio ApS
Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark. | 7 years |
Carlos Gallardo Piqué | M | - | 10 years | |
Michael McClellan | M | 54 | 5 years | |
Alexandra Kimball | M | - | 4 years | |
Ruud Dobber | M | - | - | |
Eloi Crespo Cervera | M | - | 27 years | |
Brian McGuinness | M | - |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | - |
Karin Louise Dorrepaal | M | 63 | 11 years | |
Kristine Peterson | F | 64 | 7 years | |
Theodora Caroline Harold | F | 50 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | 8 years |
Enrique de Leyva Pérez | M | 65 | 5 years | |
Graziano Seghezzi | M | 55 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | - |
Mercedes Diz | F | - | 22 years | |
Seth J. Orlow | M | - | 8 years | |
Natalie Walter | F | 50 | 6 years | |
Karl Ziegelbauer | M | - | 3 years | |
Mar Ramírez Guirao | F | - | 7 years | |
Paolo Cionini | M | - | - | |
Lucy Edwardes Jones | F | - |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 1 years |
Esteve Conesa Panicot | M | - | 22 years | |
Stefan Emanuel Luzi | M | - |
Draupnir Bio ApS
Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark. | 5 years |
Isabel Gomes | F | - | 2 years | |
Volker Koscielny | M | - | 5 years | |
Robert Scott | M | 70 |
Draupnir Bio ApS
Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark. | - |
Igor Matushansky | M | 51 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | 6 years |
Kevin Johnson | M | - |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | - |
Daniel Ripley Soria | M | 54 | - | |
Tim Funnell | M | - |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 2 years |
Antonio Gallardo Torrededía | M | - | 10 years | |
Raj Bhikhu Parekh | M | 63 |
Aleta Biotherapeutics, Inc.
Aleta Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aleta Biotherapeutics, Inc. engages in the immuno-oncology service that focuses on transforming cellular therapeutics. It allows broad spectrum of cancer indication to be targeted including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb and is headquartered in Natick, MA. | - |
Sohaib Mir | M | 42 |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 1 years |
Roel Bulthuis | M | - |
Draupnir Bio ApS
Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark. | 5 years |
Daniel Bach | M | - |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | 6 years |
Marietta Wu | M | 56 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | - |
Gilles Nobécourt | M | 67 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | - |
Simon Harford | M | 63 | 3 years | |
Thomas Weaver | M | - |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | - |
Pablo Divasson del Fraile | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jorge Gallardo Ballart | M | 82 | 57 years | |
Russell Greig | M | 71 | - | |
James Noble | M | 65 | 7 years | |
Gianfranco Nazzi | M | - | 1 years | |
Amita Kent | F | - | - | |
Craig Fox | M | - | 7 years | |
Georgia Garinois-Melenikiotou | F | 63 | 6 years | |
Peter Guenter | M | 61 | 3 years | |
Samuel Cameron Williams | M | 55 | 4 years | |
Roger Perlmutter | M | 71 | 1 years | |
Eliot Forster | M | 58 | 3 years | |
Harry Finch | M | - | 8 years | |
Remi Vermeiren | M | 84 | - | |
Mats Gunnar Pettersson | M | 78 | 6 years | |
Thomas Fulton Wilson McKillop | M | 81 | 17 years | |
Geert Cauwenbergh | M | 70 | 6 years | |
Wim Ottevaere | M | 68 | 12 years | |
Peter Pack | M | 58 |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | 4 years |
Andreas Menrad | M | 66 | 1 years | |
Catherine Tralau-Stewart | M | - | 1 years | |
John Berriman | M | 76 | 3 years | |
Roger W. Brimblecombe | M | 94 |
Vertex Pharmaceuticals (Europe) Ltd.
Vertex Pharmaceuticals (Europe) Ltd. Medical DistributorsDistribution Services Vertex Pharmaceuticals (Europe) Ltd. operates as a pharmaceutical firm. The company was founded on March 11, 1994 and is headquartered London, the United Kingdom. | - |
Sandra Orta | F | - | - | |
Christina Coughlin | M | 54 | 3 years | |
Guido Gielen | M | 64 | - | |
Yvonne McGrath | M | 50 | 4 years | |
Dominique Tersago | M | 62 | 4 years | |
Erwin Sablon | M | 59 | 2 years | |
Iain Peter Murray Buchanan | M | 72 |
Vertex Pharmaceuticals (Europe) Ltd.
Vertex Pharmaceuticals (Europe) Ltd. Medical DistributorsDistribution Services Vertex Pharmaceuticals (Europe) Ltd. operates as a pharmaceutical firm. The company was founded on March 11, 1994 and is headquartered London, the United Kingdom. | - |
Jim van Heusden | M | 53 | - | |
James Sandy | M | - | - | |
Laura Wade-Gery | F | 59 | - | |
Josefin-Beate Holz | M | 59 | 6 years | |
Christian Duby | M | - | - | |
Shah Hussain | M | 59 | 3 years | |
Mario Polywka | M | 61 | 3 years | |
Deborah Law | M | - | 1 years | |
Denis Lucquin | M | 67 | 11 years | |
Rudy Dekeyser | M | 63 | 6 years | |
Paul Fry | M | 58 | - | |
Ian Tomlinson | M | - |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 1 years |
Frank Bulens | M | 61 | 8 years | |
Alexandre Kaoukhov | M | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 36 | 41.86% |
Spain | 26 | 30.23% |
Belgium | 18 | 20.93% |
Denmark | 5 | 5.81% |
United States | 2 | 2.33% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Eva-Lotta Allan
- Personal Network